
|Slideshows|March 23, 2017
ACC 2017: Late-Breaking Clinical Trials
Author(s)Samantha J. Peterson
Research includes safety of digoxin with atrial fibrillation, comparison of cerebral embolic protection devices, and cerebral microbleed triggers.
Advertisement
Presentations during the Late-Breaking Clinical Trials session at the American College of Cardiology’s Annual Scientific Sessions included a safety investigation of digoxin use in patients with atrial fibrillation, a study of two embolic protection devices and their abilities to prevent stroke and brain infarcts, and possible triggers of cerebral microbleeds during transacatheter aortic valve replacement.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis
2
Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers
3
Using Human iPSC Models to Dissect PIRA Mechanisms in Progressive Multiple Sclerosis: Valentina Fossati, PhD
4
Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis
5








